How did lomustine become standard of care in recurrent glioblastoma?

Nikolova, 2017, Chloroethylating nitrosoureas in cancer therapy: DNA damage, repair and cell death signaling, Biochim Biophys Acta Rev Cancer, 1868, 29, 10.1016/j.bbcan.2017.01.004 Puyo, 2014, From old alkylating agents to new minor groove binders, Crit Rev Oncol Hematol, 89, 43, 10.1016/j.critrevonc.2013.07.006 Kaina, 2019, DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas, DNA Repair (Amst), 78, 128, 10.1016/j.dnarep.2019.04.007 Wick, 2010, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol, 28, 1168, 10.1200/JCO.2009.23.2595 Batchelor, 2013, Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma, J Clin Oncol, 31, 3212, 10.1200/JCO.2012.47.2464 Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, 15, 943, 10.1016/S1470-2045(14)70314-6 Brandes, 2016, A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma, Neuro-Oncology, 18, 1146, 10.1093/neuonc/now009 Wick, 2017, Lomustine and bevacizumab in progressive glioblastoma, N Engl J Med, 377, 1954, 10.1056/NEJMoa1707358 Duerinck, 2018, Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma, J Neurooncol, 136, 115, 10.1007/s11060-017-2629-z Lombardi, 2019, Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial, Lancet Oncol, 20, 110, 10.1016/S1470-2045(18)30675-2 van den Bent, 2019, INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFRamplified glioblastoma, Neuro-Oncology Medical Research Council Brain Tumor Working Party, 2001, Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial, J Clin Oncol, 19, 509, 10.1200/JCO.2001.19.2.509 Herrlinger, 2019, Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial, Lancet, 393, 678, 10.1016/S0140-6736(18)31791-4 Gutin, 1975, Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors, Cancer, 35, 1398, 10.1002/1097-0142(197505)35:5<1398::AID-CNCR2820350524>3.0.CO;2-C Brada, 2010, Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma, J Clin Oncol, 28, 4601, 10.1200/JCO.2009.27.1932 Cairncross, 2013, Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402, J Clin Oncol, 31, 337, 10.1200/JCO.2012.43.2674 van den Bent, 2013, Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951, J Clin Oncol, 31, 344, 10.1200/JCO.2012.43.2229 Buckner, 2016, Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma, N Engl J Med, 374, 1344, 10.1056/NEJMoa1500925 Glas, 2011, NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri, Ann Neurol, 70, 445, 10.1002/ana.22478 Vesper, 2009, Retrospective analysis of treatment outcome in 315 patients with oligodendroglial brain tumors, BMC Neurol, 9, 33, 10.1186/1471-2377-9-33 Webre, 2015, PC or PCV, that is the question: primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine, Anticancer Res, 35, 5467 Yung, 2000, A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, Br J Cancer, 83, 588, 10.1054/bjoc.2000.1316 Herrlinger, 2006, Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03, J Clin Oncol, 24, 4412, 10.1200/JCO.2006.06.9104 Glas, 2009, Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide, J Clin Oncol, 27, 1257, 10.1200/JCO.2008.19.2195 Jakacki, 2008, A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood, Neuro-Oncology, 10, 569, 10.1215/15228517-2008-019 Jakacki, 2016, Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children’s Oncology Group ACNS0423 study, Neuro-Oncology, 18, 1442, 10.1093/neuonc/now038 Fu, 2012, Balancing repair and tolerance of DNA damage caused by alkylating agents, Nat Rev Cancer, 12, 104, 10.1038/nrc3185 Gilbert, 2013, Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J Clin Oncol, 31, 4085, 10.1200/JCO.2013.49.6968 Baehring, 2012, Treatment-related myelodysplasia in patients with primary brain tumors, Neuro-Oncology, 14, 529, 10.1093/neuonc/nos068 Weller, 2017, European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas, Lancet Oncol, 18, e315, 10.1016/S1470-2045(17)30194-8 Alexander, 2018, Adaptive global innovative learning environment for glioblastoma: GBM AGILE, Clin Cancer Res, 24, 737, 10.1158/1078-0432.CCR-17-0764 Le Rhun, 2019, Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial, Neurology, 93, e1799, 10.1212/WNL.0000000000008440